Furthermore, cases of HER2-positive breast cancer treated with neoadjuvant chemotherapy without anti-HER2 agents were also included to explore whether the predictive value of IBMs was dependent on anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast carcinoma.